A pilot study of neoadjuvant non-fucosylated anti-CTLA-4 (BMS-986218) + degarelix acetate vs. degarelix acetate alone in men with high risk localized prostate cancer
Study of BMS-986218 + Degarelix Acetate vs. Degarelix Acetate Alone in Men with Prostate Cancer
Sponsor: BMS, Ferring Pharmaceuticals, and Prostate Cancer Foundation
Enrolling: Male Patients Only
IRB Number: AAAS3560
U.S. Govt. ID: NCT04301414
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses your testosterone) given prior to surgery can decrease the chance that your cancer will come back compared to degarelix alone. People who usually have this type of prostate cancer usually do not receive any additional therapy prior to surgery.
This study is closed
Investigator
Karie D. Runcie, MD
Do You Qualify?
Are you a male of at least 18 years of age? Yes No
Have you been diagnosed with prostate cancer? Yes No
Are you able to do everyday work independently? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE